Next report date
Report period
Q1 2024
EPS estimate
−39.05MXN
Revenue estimate
445.74 MMXN
−54.48MXN
−3.14 BMXN
1.32 BMXN
53.26 M
About Rhythm Pharmaceuticals, Inc.
Sector
Industry
CEO
David P. Meeker
Website
Headquarters
Boston
Employees (FY)
226
Founded
2008
FIGI
BBG00PGH17C9
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RYTM is 680.21 MXN — it has increased by 5.15% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange RHYTHM PHARMACEUTICALS INC stocks are traded under the ticker RYTM.
RHYTHM PHARMACEUTICALS INC is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
RYTM stock is 4.90% volatile and has beta coefficient of 2.39. Check out the list of the most volatile stocks — is RHYTHM PHARMACEUTICALS INC there?
RYTM earnings for the last quarter are −13.25 MXN per share, whereas the estimation was −12.90 MXN resulting in a −2.70% surprise. The estimated earnings for the next quarter are −11.98 MXN per share. See more details about RHYTHM PHARMACEUTICALS INC earnings.
RHYTHM PHARMACEUTICALS INC revenue for the last quarter amounts to 392.26 M MXN despite the estimated figure of 386.58 M MXN. In the next quarter revenue is expected to reach 431.08 M MXN.
Yes, you can track RHYTHM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
RYTM stock has risen by 5.15% compared to the previous week, the month change is a 5.15% rise, over the last year RHYTHM PHARMACEUTICALS INC has showed a 84.25% increase.
RYTM net income for the last quarter is −706.94 M MXN, while the quarter before that showed −769.79 M MXN of net income which accounts for 8.17% change. Track more RHYTHM PHARMACEUTICALS INC financial stats to get the full picture.
Today RHYTHM PHARMACEUTICALS INC has the market capitalization of 39.61 B, it has increased by 1.68% over the last week.
No, RYTM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RYTM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade RHYTHM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 226.00 employees. See our rating of the largest employees — is RHYTHM PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So RHYTHM PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating RHYTHM PHARMACEUTICALS INC stock shows the buy signal. See more of RHYTHM PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on RHYTHM PHARMACEUTICALS INC future price: according to them, RYTM price has a max estimate of 1371.58 MXN and a min estimate of 840.09 MXN. Read a more detailed RHYTHM PHARMACEUTICALS INC forecast: see what analysts think of RHYTHM PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. RHYTHM PHARMACEUTICALS INC EBITDA is −3.10 B MXN, and current EBITDA margin is −235.83%. See more stats in RHYTHM PHARMACEUTICALS INC financial statements.